223 related articles for article (PubMed ID: 34061962)
1. Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease.
Araki T; Tone Y; Yamamoto M; Kameda H; Ben-Shlomo A; Yamada S; Takeshita A; Yamamoto M; Kawakami Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3346-e3363. PubMed ID: 34061962
[TBL] [Abstract][Full Text] [Related]
2. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
[TBL] [Abstract][Full Text] [Related]
3. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Fukuoka H; Cooper O; Ben-Shlomo A; Mamelak A; Ren SG; Bruyette D; Melmed S
J Clin Invest; 2011 Dec; 121(12):4712-21. PubMed ID: 22105169
[TBL] [Abstract][Full Text] [Related]
4. Why don't corticotroph tumors always produce Cushing's disease?
García-Martínez A; Cano DA; Flores-Martínez A; Gil J; Puig-Domingo M; Webb SM; Soto-Moreno A; Picó A
Eur J Endocrinol; 2019 Sep; 181(3):351-361. PubMed ID: 31319379
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin-Specific Protease 8 Mutant Corticotrope Adenomas Present Unique Secretory and Molecular Features and Shed Light on the Role of Ubiquitylation on ACTH Processing.
Sesta A; Cassarino MF; Terreni M; Ambrogio AG; Libera L; Bardelli D; Lasio G; Losa M; Pecori Giraldi F
Neuroendocrinology; 2020; 110(1-2):119-129. PubMed ID: 31280266
[TBL] [Abstract][Full Text] [Related]
6. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.
Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J
Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723
[TBL] [Abstract][Full Text] [Related]
7. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
[TBL] [Abstract][Full Text] [Related]
8. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome.
de Keyzer Y; Lenne F; Auzan C; Jégou S; René P; Vaudry H; Kuhn JM; Luton JP; Clauser E; Bertagna X
J Clin Invest; 1996 Mar; 97(5):1311-8. PubMed ID: 8636444
[TBL] [Abstract][Full Text] [Related]
9. AZA-deoxycytidine stimulates proopiomelanocortin gene expression and ACTH secretion in human pituitary ACTH-secreting tumors.
Cassarino MF; Sesta A; Pagliardini L; Losa M; Lasio G; Cavagnini F; Pecori Giraldi F
Pituitary; 2014 Oct; 17(5):464-9. PubMed ID: 24085685
[TBL] [Abstract][Full Text] [Related]
10. Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease.
Du L; Bergsneider M; Mirsadraei L; Young SH; Jonker JW; Downes M; Yong WH; Evans RM; Heaney AP
Proc Natl Acad Sci U S A; 2013 May; 110(21):8555-60. PubMed ID: 23653479
[TBL] [Abstract][Full Text] [Related]
11. E2F1-mediated human POMC expression in ectopic Cushing's syndrome.
Araki T; Liu NA; Tone Y; Cuevas-Ramos D; Heltsley R; Tone M; Melmed S
Endocr Relat Cancer; 2016 Nov; 23(11):857-870. PubMed ID: 27935805
[TBL] [Abstract][Full Text] [Related]
12. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.
Morris DG; Kola B; Borboli N; Kaltsas GA; Gueorguiev M; McNicol AM; Ferrier R; Jones TH; Baldeweg S; Powell M; Czirják S; Hanzély Z; Johansson JO; Korbonits M; Grossman AB
J Clin Endocrinol Metab; 2003 Dec; 88(12):6080-7. PubMed ID: 14671214
[TBL] [Abstract][Full Text] [Related]
13. Differential gene expression in ACTH -secreting and non-functioning pituitary tumors.
Tateno T; Izumiyama H; Doi M; Yoshimoto T; Shichiri M; Inoshita N; Oyama K; Yamada S; Hirata Y
Eur J Endocrinol; 2007 Dec; 157(6):717-24. PubMed ID: 18057378
[TBL] [Abstract][Full Text] [Related]
14. Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
Sekizaki T; Kameda H; Nakamura A; Kuwabara S; Nomoto H; Cho KY; Ishi Y; Motegi H; Miyoshi H; Atsumi T
Pituitary; 2023 Oct; 26(5):597-610. PubMed ID: 37642928
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation.
Kageyama K; Asari Y; Sugimoto Y; Niioka K; Daimon M
Endocr J; 2020 Feb; 67(2):177-184. PubMed ID: 31666445
[TBL] [Abstract][Full Text] [Related]
16. Targeting the ERK pathway for the treatment of Cushing's disease.
Zhang D; Bergsneider M; Wang MB; Heaney AP
Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
[TBL] [Abstract][Full Text] [Related]
17. Loss of ACTH expression in cultured human corticotroph macroadenoma cells is consistent with loss of the POMC gene signal sequence.
Rees DA; Hepburn PJ; McNicol AM; Francis K; Jasani B; Lewis MD; Farrell WE; Lewis BM; Scanlon MF; Ham J
Mol Cell Endocrinol; 2002 Mar; 189(1-2):51-7. PubMed ID: 12039064
[TBL] [Abstract][Full Text] [Related]
18. O-GlcNAcylation Is Essential for Rapid Pomc Expression and Cell Proliferation in Corticotropic Tumor Cells.
Massman LJ; Pereckas M; Zwagerman NT; Olivier-Van Stichelen S
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34418053
[TBL] [Abstract][Full Text] [Related]
19. Central dysregulation of the hypothalamic-pituitary-adrenal axis in neuron-specific proopiomelanocortin-deficient mice.
Smart JL; Tolle V; Otero-Corchon V; Low MJ
Endocrinology; 2007 Feb; 148(2):647-59. PubMed ID: 17095588
[TBL] [Abstract][Full Text] [Related]
20. PATHOGENESIS OF CUSHING DISEASE: AN UPDATE ON THE GENETICS OF CORTICOTROPINOMAS.
Albani A; Perez-Rivas LG; Reincke M; Theodoropoulou M
Endocr Pract; 2018 Oct; 24(10):907-914. PubMed ID: 30084690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
